USPTO serial 76410122
AMERSHAM
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jan 27, 2004
- Examiner
- BELL, MARLENE D
- Law office
- GENERIC WEB UPDATE
What this means
Status 800 means the registration was renewed after acceptable combined Section 8 and Section 9 filings. The mark remains registered for another 10-year term with active federal protection. Calendar the next Section 8 and 9 deadline in 10 years and maintain monitoring.
Need help with AMERSHAM?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Buckinghamshire
Buckinghamshire
Buckinghamshire
BUCKINGHAMSHIRE, GB
GLOBAL LIFE SCIENCES SOLUTIONS OPERATIONS UK LTD
Buckinghamshire, GB
Other trademarks owned by GLOBAL LIFE SCIENCES SOLUTIONS OPERATIONS UK LTD
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Dyan M. House
Dyan M. House Baker & Mckenzie, LLP1900 N. Pearl Street, Suite 1500Dallas, TX 75201United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals, biochemicals and reagents for use in industry, science and research, namely, nucleotides, fluorescent nucleotides, oligonucleotides, peptides, proteins, amino acids, organic molecules, markers for DNA/RNA synthesis; reagents for luminescence; reagents for gene expression quantification; reagents for use with the polymerase chain reaction, PCR, process and the rolling circle amplification (RCA) process; reagents for cDNA cloning vectors, modifying and restriction enzymes; reagents for labeling, detecting sequencing and fragment analysis of nucleic acids, proteins, and custom synthesis; reagents for recombinant protein expression purification, chromatography media; electrophoresis; spectrophotometry and fluorometry; [ radiochemicals; scintillation assays; and high through put screening assays for drug development; and chemical preparations and substances for use in the manufacture of pharmaceutical products; diagnostic preparations and substances; chemical test reagents, saline solution and reagent-coated paper, all for scientific and laboratory use; fissionable chemical elements; radioactive elements and isotopes for industrial, scientific, and research purposes; radioactive sources and standards for use in radiographic techniques; radioactive sources for use in non-destructive testing, purification or sterilizing techniques for use in industry, science and research; chemical preparations, kits and reagents for analysis or diagnosis used for scientific purposes, namely, cell separation and culture; ] nucleic acid purification [ ; and radionuclides, gases and gas mixtures for industrial, scientific, and research purposes ] | ACTIVE | — |
| 005 | [ Diagnostic agents, preparations and substances for medical purposes; Contrast media for medical imaging; diagnostic scanning agents for in vivo use; radiopharmaceutical products for clinical, medical and research use; radioactive sources and standards for use in nuclear medicine; radioactive pharmaceutical preparations and non-radioactive reagents for producing radiopharmaceuticals for in vivo diagnostic or therapeutic use; pharmaceutical preparations for use in diagnosis; pre-filled vials and cartridges containing medical diagnostic reagents or saline solution; and radioisotope brachytherapy substances ] | SECTION 8 - CANCELLED | — |
| 009 | [ Scientific apparatus and instruments used for radiology for the purpose of measuring, monitoring and surveying; computers, printers, and software programs used for the purpose of life science research and for nuclear cardiology and medical imaging, for use by laboratories, pharmacies, doctors, hospitals, and medical service providers; radiology apparatus and instruments for the reading and interpretation of autoradiographs and films, namely, automated film readers and scanners; apparatus for electrophoresis; chromatography columns and pumps; apparatus for microfabrication; apparatus for scintillation; imaging apparatus for radioactive and luminescent emissions; synthesis and purification integrated systems for use in radiology; apparatus for manufacturing oligonucleotides; apparatus for microarrays; microarray slides; laboratory glassware; laboratory vials and microvials; microtitre plates; and parts and fittings for the aforesaid goods ] | SECTION 8 - CANCELLED | — |
| 010 | [ Surgical, medical, dental, and veterinary apparatus and instruments used for the purpose of measuring, monitoring and surveying in the field of radiotherapy, comprised of medical needles, suture needles, implantable radiation therapy devices and implantable radiation therapy devices consisting of encapsulated radioisotope brachytherapy sources, radiation therapy delivery system consisting primarily of radioactive seeds and a bio-absorbable carrier assembly; magnetic resonance imagers, MRI; x-ray apparatus for medical use; x-ray diagnostic apparatus, computerized tomography, CAT scanners and ultrasound imagers; radiological apparatus for diagnostic and medical purposes; diagnostic and test kits for clinical medical use comprised of test tubes, test plates and indicator charts for evaluating test results; vials; cannulas; needles and syringes; injectors; cartridges; infusion pumps for intravenous administration of fluids; needles for medical purposes; and parts and fittings for the aforesaid goods ] | SECTION 8 - CANCELLED | — |
| 042 | [ Advisory services for pharmaceutical companies in the field of purification and chromatography; research and development services in the field of pharmaceutical and life sciences; research and product development for others, namely, research and development of pharmaceutical, medical, and veterinary preparations, diagnostic media and agents for use in medical and diagnostic imaging; consultancy services relating to chemical and pharmaceutical research; analytical services in the fields of medicine, pharmaceuticals and biochemistry; radiolableling services, namely, isotopic labeling of biological molecules; pharmaceutical drug development services for pharmaceutical companies and medical professionals ] | SECTION 8 - CANCELLED | — |
| 044 | [ Medical diagnostic services; medical imaging services; providing medical and medical product information to pharmaceutical companies and medical professionals ] | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by AMERSHAM PLC
- Other trademarks owned by AMERSHAM PLC
- Other trademarks owned by AMERSHAM PLC
- Other trademarks owned by GE HEALTHCARE LIMITED
- Other trademarks owned by GLOBAL LIFE SCIENCES SOLUTIONS OPERATIONS UK LTD
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named AMERSHAM
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 26, 2024 | NA89 | NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED | — |
| Apr 26, 2024 | RNL2 | REGISTERED AND RENEWED (SECOND RENEWAL - 10 YRS) | The trademark registration was renewed for another 10-year term after acceptable maintenance filings. RNL1, RNL2, and RNL3 indicate which renewal cycle (first, second, or third 10-year term) was recorded. The registration remains active. |
| Apr 26, 2024 | 89AG | REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED | The USPTO accepted your combined Section 8 declaration and Section 9 renewal application. The registration is renewed for another 10-year term. The next combined maintenance filing will be due at the following 10-year anniversary. |
| Apr 26, 2024 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Dec 28, 2023 | E89R | TEAS SECTION 8 & 9 RECEIVED | — |
| Sep 22, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Sep 22, 2023 | EWOR | TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED | — |
| Sep 22, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 22, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Sep 22, 2023 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Sep 22, 2023 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jan 27, 2023 | REM2 | COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED | — |
| Oct 7, 2020 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Jul 28, 2014 | NAS8 | NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED | — |
| Jul 28, 2014 | RNL1 | REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS) | The trademark registration was renewed for another 10-year term after acceptable maintenance filings. RNL1, RNL2, and RNL3 indicate which renewal cycle (first, second, or third 10-year term) was recorded. The registration remains active. |
| Jul 28, 2014 | 9G8P | REGISTERED - SEC. 9 GRANTED/CHECK RECORD FOR SEC. 8 | — |
| Jul 28, 2014 | 8PRT | REGISTERED - PARTIAL SEC. 8 (10-YR) ACCEPTED | — |
| Jul 24, 2014 | E89R | TEAS SECTION 8 & 9 RECEIVED | — |
| Feb 11, 2010 | C15P | REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| Feb 10, 2010 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Feb 2, 2010 | 815F | REGISTERED - SEC. 8 (6-YR) & SEC. 15 FILED | — |
| Feb 2, 2010 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Jun 7, 2007 | CFIT | CASE FILE IN TICRS | — |
| Feb 18, 2005 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 18, 2005 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 27, 2004 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 4, 2003 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 15, 2003 | NPUB | NOTICE OF PUBLICATION | — |
| Jun 24, 2003 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 24, 2003 | CNEA | EXAMINERS AMENDMENT MAILED | — |
| Jun 16, 2003 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Mar 21, 2003 | 1.BD | Sec. 1(B) CLAIM DELETED | — |
| Mar 10, 2003 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 28, 2003 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 28, 2003 | PAPER RECEIVED | — | |
| Dec 6, 2002 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 27, 2002 | CNEA | EXAMINERS AMENDMENT MAILED | — |
| Aug 27, 2002 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |